Martin Rhiel

Title: Martin Rhiel: Innovator in Scalable Fermentation Processes

Introduction

Martin Rhiel is a notable inventor based in Bonstetten, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of scalable fermentation processes. His innovative work focuses on enhancing the production of capsid proteins, which are essential for various applications in virology and vaccine development.

Latest Patents

Rhiel holds a patent for a scalable fermentation process. This invention provides a robust method for the expression of a capsid protein of a bacteriophage that forms a virus-like particle (VLP) through self-assembly. The process is designed to be scalable to commercial production levels, with a controlled expression rate of the capsid protein to improve the yield of soluble capsid protein. This is achieved by integrating the benefits of fed-batch culture and lactose-induced expression systems, along with specific process parameters that enhance promoter repression during the growth phase and ensure high plasmid retention throughout the process. He has 1 patent to his name.

Career Highlights

Throughout his career, Martin Rhiel has worked with prominent companies in the biotechnology sector. Notably, he has been associated with Kuros Biosciences AG and Cytos Biotechnology AG. His experience in these organizations has allowed him to refine his expertise in fermentation processes and protein expression.

Collaborations

Rhiel has collaborated with several professionals in his field, including Marcel Emmerling and Frank Hennecke. These collaborations have contributed to the advancement of his research and the successful implementation of his innovative processes.

Conclusion

Martin Rhiel's contributions to scalable fermentation processes highlight his role as an influential inventor in biotechnology. His patented methods are paving the way for improved production techniques in the industry.